Immunotherapeutic Strategies for Substance Use Disorders

Immunotherapeutic approaches to substance use disorders harness the specificity of the immune system to intercept and neutralise addictive compounds before they reach central targets. Two principal strategies have emerged: passive immunisation, employing high-affinity monoclonal antibodies that bind drugs of abuse in the circulation, and active immunisation, in which vaccines comprising small-molecule haptens conjugated to carrier proteins elicit drug-specific antibodies. Advances in hapten design, carrier selection and adjuvant formulations have improved the magnitude and durability of antibody responses, thereby reducing central nervous system penetration of opioids, nicotine and stimulants. Moreover, modulation of cytokine signalling pathways has been explored to enhance vaccine efficacy in individuals with suboptimal antibody titres. Collectively, these immunotherapies offer a dual benefit: prevention of drug-induced reward and mitigation of overdose risk. Ongoing work addresses translation to clinical use, optimal dosing regimens, and integration with behavioural and pharmacological treatments on a global scale.

Research from Nature Portfolio

Recent studies have developed a fully human monoclonal antibody with picomolar affinity for fentanyl and its analogues. In preclinical models, a single administration reversed fentanyl-induced respiratory depression and antinociception, offering multi-week protection without cross-reactivity to other opioids. Toxicokinetic data demonstrate a favourable safety profile, supporting clinical readiness. In parallel, research has shown that blocking interleukin-4 signalling enhances the immunogenicity of conjugate vaccines against oxycodone by promoting stronger B cell responses. Pharmacological inhibition of this cytokine pathway led to higher antibody titres, greater blockade of central drug distribution and improved protection against opioid-induced toxicity. This cytokine-targeted approach provides a blueprint for next-generation vaccine adjuvantation to overcome individual variability in antibody responses.

Immunotherapeutic Strategies for Substance Use Disorders publication trend

The graph below shows the total number of articles in immunotherapeutic strategies for substance use disorders across all publications each year (not limited to Nature Index journals).

Technical terms

Monoclonal antibody: Homogeneous immunoglobulin produced by a single B cell clone that binds a specific antigen epitope with high selectivity.

Hapten: Small molecule that becomes immunogenic only when covalently linked to a larger carrier protein, enabling antibody generation against the drug moiety.

Adjuvant: Substance added to a vaccine formulation to enhance the magnitude and quality of the immune response to the antigen.

Immunogenicity: Capacity of an antigen or vaccine to provoke an adaptive immune response, including antibody production and memory cell formation.

Cytokine: Small secreted protein that mediates intercellular communication within the immune system and regulates inflammation and lymphocyte activation.

References

1. Investigation of monoclonal antibody CSX-1004 for fentanyl overdose. Nature Communications (2023).
2. Blocking interleukin-4 enhances efficacy of vaccines for treatment of opioid abuse and prevention of opioid overdose. Scientific Reports (2018).
3. A Vaccine against Nicotine for Smoking Cessation: A Randomized Controlled Trial. PLOS ONE (2008).
4. Safety and efficacy of an oxycodone vaccine: Addressing some of the unique considerations posed by opioid abuse. PLOS ONE (2017).
5. Fentanyl conjugate vaccine by injected or mucosal delivery with dmLT or LTA1 adjuvants implicates IgA in protection from drug challenge. npj Vaccines (2021).